Back to the bench? MEK and ERK inhibitors for the treatment of KRAS mutant lung adenocarcinoma

J Kohler, M Catalano… - Current Medicinal …, 2018 - ingentaconnect.com
Background: Lung cancer accounts for one in five cancer deaths worldwide and mutations in
the gene encoding for the Kirsten rat sarcoma (KRAS) oncoprotein define the largest …
被引用次数：15 相关文章

Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma

J Kohler, M Catalano… - Current medicinal …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Lung cancer accounts for one in five cancer deaths worldwide and mutations in
the gene encoding for the Kirsten rat sarcoma (KRAS) oncoprotein define the largest …

Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma

J Kohler, M Catalano, C Ambrogio - Current Medicinal Chemistry, 2018 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> Lung cancer accounts for one
in five cancer deaths worldwide and mutations in the gene encoding for the Kirsten rat …

Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma.

J Kohler, M Catalano, C Ambrogio - Current Medicinal Chemistry, 2018 - europepmc.org
Background Lung cancer accounts for one in five cancer deaths worldwide and mutations in
the gene encoding for the Kirsten rat sarcoma (KRAS) oncoprotein define the largest …